Switch in FGFR3 and-4 Expression Profile During Human Renal Development May Account for Transient Hypercalcemia in Patients With Sotos Syndrome due to 5q35 Microdeletions by Mutsaers, Henricus A. M et al.
  
 
 
 
 
 
 
 
 
Citation MUTSAERS H.A., LEVTCHENKO E.N., MARTINERIE L., PERTIJS 
J.C., ALLEGAERT K., DEVRIENDT K., MASEREEUW R., 
MONNENS L.A., LOMBES M. (2014), 
Switch in FGFR3 and -4 Expression Profile During Human Renal 
Development May Account for Transient Hypercalcemia in Patients 
With Sotos Syndrome due to 5q35 Microdeletions 
J Clin Endocrinol. Metab, 99(7), E1361-E1367 
Archived version Final publisher’s version / pdf 
Published version http://press.endocrine.org/doi/full/10.1210/jc.2014-1123 
doi: http://dx.doi.org/10.1210/jc.2014-1123 
Journal homepage http://press.endocrine.org/journal/jcem/ 
Author contact  
Klik hier als u tekst wilt invoeren. 
IR https://lirias.kuleuven.be/handle/123456789/450417 
 
(article begins on next page) 
 
Switch in FGFR3 and -4 Expression Profile During
Human Renal Development May Account for
Transient Hypercalcemia in Patients With Sotos
Syndrome due to 5q35 Microdeletions
Henricus A. M. Mutsaers, Elena N. Levtchenko, Laetitia Martinerie,
Jeanne C. L. M. Pertijs, Karel Allegaert, Koenraad Devriendt,
Rosalinde Masereeuw, Leo A. H. Monnens, and Marc Lombès
Institut National de la Santé et de la Recherche Médicale (H.A.M.M., L.M., M.L.), Unité 693, Faculté de
Médecine Paris-Sud, 94276 Le Kremlin-Bicêtre, France; PremUP Foundation (L.M., M.L.), 75014 Paris,
France; Departments of Pharmacology and Toxicology (H.A.M.M., J.C.L.M.P., R.M.), Physiology
(L.A.H.M.), Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands; and Departments
of Pediatrics and Growth and Regeneration (E.N.L., K.A.) and Center for Human Genetics (K.D.),
University Hospitals Leuven and Katholieke Universiteit Leuven, 3000 Leuven, Belgium
Context: Sotos syndrome is a rare genetic disorder with a distinct phenotypic spectrum including
overgrowth and learning difficulties. Here we describe a new case of Sotos syndrome with a 5q35
microdeletion, affecting the fibroblast growth factor receptor 4 (FGFR4) gene, presenting with
infantile hypercalcemia.
Objective:Westrove toelucidate theevanescentnatureof theobservedhypercalcemiaby studying
theontogenesis of FGFR3andFGFR4,whicharebothassociatedwith fibroblastgrowth factor (FGF)
23-mediated mineral homeostasis, in the developing human kidney.
Design:QuantitativeRT-PCRand immunohistochemical analyseswereusedonarchival humankidney
samples to investigate the expression of the FGFR signaling pathway during renal development.
Results:Wedemonstrated that renal gene and protein expression of both FGFRs increased during
fetal development between the gestational ages (GAs) of 14–40 weeks. Yet FGFR4 expression
increasedmore rapidly as comparedwith FGFR3 (slope 0.047 vs 0.0075, P .0018).Moreover, gene
and protein expression of the essential FGFR coreceptor, Klotho, also increased with a significant
positive correlation between FGFR and Klotho mRNA expression during renal development. In-
terestingly, we found that perinatal FGFR4 expression (GA 38–40 wk) was 7-fold higher as com-
pared with FGFR3 (P  .0035), whereas in adult kidney tissues, FGFR4 gene expression level was
more than 2-fold lower compared with FGFR3 (P  .0029), thus identifying a molecular develop-
mental switch of FGFR isoforms.
Conclusion:Wepropose that the heterozygous FGFR4deletion, as observed in the Sotos syndrome
patient, leads to a compromised FGF23 signaling during infancy accounting for transient hyper-
calcemia. These findings represent a novel and intriguing view on FGF23 mediated calcium
homeostasis. (J Clin Endocrinol Metab 99: E1361–E1367, 2014)
Sotos syndrome is an autosomal dominant disordercharacterizedbyovergrowth, learningdisability, and
distinctive facial features such asmacrocephaly (1, 2). The
syndrome results frommutations and deletions, mostly de
novo, of theNSD1 gene located at chromosome 5, which
encodes for the nuclear receptor-binding SET (Su(var)3-9,
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Enhancer-of-zeste, Trithorax) domain containing protein
1 (NSD1).Little is knownregarding the functionofNSD1,
and it remains unclear how theNSD1 gene inactivation or
NSD1 dysfunction may cause the Sotos phenotype (3).
Intragenic mutations are responsible for 80%–85% of
Sotos syndrome cases, whereas 5q35 microdeletions en-
compassingNSD1 cause10%–15%of the cases inEurope
and the United States (4). Of note, 5q35 microdeletions
vary in size, from 0.4 to 5Mb and may affect genes flank-
ing NSD1 (5). Saugier-Veber et al (6) mentioned the oc-
currence of nephrocalcinosis in three patients with large
deletions and suggested the presence of a predisposing
gene in the deleted area. This phenotype spectrum was
confirmed by Kenny et al (7), who reported two unrelated
cases of Sotos syndromeassociatedwithnephrocalcinosis,
one of whom had proven infantile hypercalcemia. The
authors suggested that the heterozygous deletion of
SLC34A1, encoding the main sodium phosphate cotrans-
porter NPT2a, could explain the temporary hypercalce-
mia in these patients.However, hypercalcemiawas absent
in patients with a loss of function of sodium-phosphate
transport protein 2a, as described by Magen et al (8), in
contrast to Npt2/ mice that exhibited a slight but sig-
nificant increase in serum calcium concentration com-
pared with wild-type mice (9). Thus, the transient nature
of the hypercalcemia remains unexplained in Sotos syn-
drome patients.
Another gene mapped to the deletion interval is FGFR4,
encoding for the fibroblast growth factor receptor (FGFR)4.
The fibroblast growth factors (FGFs) are a large family of
peptides thatare involved inamyriadofbiologicalprocesses,
including development and mineral homeostasis (10). Cur-
rently seven FGF subfamilies have been identified encom-
passing22differentFGFs.TheFGF19subfamily, containing
FGF19, FGF21, and FGF23, plays a key role in regulating
energyandmineralmetabolism(10).Of interest,FGF23 isof
theutmost importance inmaintainingvitaminD,phosphate,
and calcium levels (11). FGF23 is a ligand for several FGFRs
(eg, FGFR1, FGFR3, and FGFR4), and it has been demon-
strated that Klotho forms a complex with these receptors,
resulting in an increased affinity selectively to FGF23 (10,
12).FGFR1is implicated in theFGF23effectsonNPT2aand
NPT2ccotransporters (13),whereasFGFR3andFGFR4are
linked toFGF23effectsonvitaminDandcalciumlevels (14).
Thus, there is a clear link between FGFR4-mediated FGF23
signaling and calcium homeostasis. Here we describe a new
Sotos syndrome case, due to a 5q35 microdeletion, with in-
fantile hypercalcemia, andwe hypothesized that a heterozy-
gousmutation inFGFR4mightbeapossible explanation for
the observed elevated calcium levels. To unravel the tempo-
rary characteristics of the perceived hypercalcemia,we stud-
iedFGFR3andFGFR4ontogenesis in thehumandeveloping
kidney that has never been reported to date.
Materials and Methods
Ethics statement
Fetal sampleswere collectedafterparental informedandwrit-
ten consent and after declaration to the French Biomedical
Agency (Decree 003812, September 22, 2006). Archival formol-
fixed, paraffin-embedded fetal and neonatal kidneys were se-
lected from the collections of several departments of pathology
according to the French legislation. Parental informed and writ-
ten consents had been obtained at the time of tissue collection
and were conserved in each department. Experimental use of
these sampleshasbeendeclared to theFrenchBiomedicalAgency
(Decree 003812, September 22, 2006).
Human renal samples
Snap-frozen kidney samples from 18 fetuses, with a gesta-
tional age of 14–40 weeks, obtained from the Department of
Fetopathology of Robert-Debré University Hospital (Paris,
France) were used for quantitative PCR (qPCR). For histology,
a selection was made from 37 archival tissue sections previously
checked for quality and integrity by immunostaining with vi-
mentin and low-molecular-weight cytokeratin (15).
Quantitative PCR
To study gene expression, total RNA (1g) was reverse tran-
scribed using 50 UMultiScribe reverse transcriptase (Life Tech-
nologies). Subsequently, cDNA was used for qPCR performed
with a StepOnePlus real-time PCR system using the TaqMan
universal PCR master mix (Life Technologies). GAPDH was
used as housekeeping gene, and relativemRNAexpression levels
were calculatedusing the equation, (2-CT)100, or as fold change
using the 2-CT method. The following primer-probe sets were
used: FGFR3, Hs00179829_m1; FGFR4, Hs01106908_m1;
GAPDH, Hs99999905_m1; and Klotho, Hs00183100_m1 (all
obtained from Life Technologies).
Immunohistochemistry
Five-micrometer-thick tissue sections were deparaffinized
and rehydrated in successive baths of xylene and graded alco-
hols. Afterward, the slides were heated in sodium citrate buffer
(pH 6) at 100°C for 15 minutes. Endogenous peroxidase was
blocked with 3% (vol/vol) H2O2 for 30 minutes. Next, nonspe-
cific epitopes were blocked for 30 minutes at room temperature
with 1% (w/vol) BSA in PBS containing 0.1% (vol/vol) Tween-
20. Subsequently, the slides were incubated overnight at 4°C
with rabbit--FGFR3 (1:1000; ab137084; Abcam), rabbit--
FGFR4 (1:500; ab41948; Abcam), or rabbit--Klotho (1:100;
ab181373; Abcam) in a blocking buffer. To reveal bound Ig,
slides were incubated for 30 minutes at room temperature with
the ImmPRESS antirabbit Ig kit (Vector), and liquid diamino-
benzidine plus chromogene (Dako) was used for visualization.
Slides were counterstained with Mayer’s hematoxylin and
mounted using Glycergel (Dako). Sections were studied via
bright-field microscopy (Olympus BX61), and images were
taken by means of a Retiga-2000R Fast 1394 digital camera
(QImaging).
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Statistics
Statisticswere performed usingGraphPad Prism version 6.03
via a one-way ANOVA followed by Bonferroni’s multiple com-
parison test or an unpaired Student’s t test. Differences between
groups were considered to be statistically significant when P 
.05. The software was also used to perform linear regression
analyses and correlation analyses (Pearson and Spearman).
Results
Case report of a new Sotos syndrome patient with
5q35 microdeletion and infantile hypercalcemia
Subject G was the fourth child of nonconsanguineous
parents. His birth weight was 3580 g after 39 weeks of an
uncomplicated pregnancy. A short period of artificial ven-
tilationwas required after birthdue to respiratorydistress.
Because of dysmorphic features, an array comparative
genomic hybridization was performed, which revealed a
microdeletion at 5q35, including bothNSD1 and FGFR4,
as shown in Figure 1A. The deletion was absent in both
parents, suggesting that it occurred de novo. In addition,
hypercalcemia was observed during the first 2 weeks of
life, as presented in Figure 1B, and normalized afterward.
In the first weeks after birth from day 8 to day 18, serum
phosphate levels were slightly reduced ranging from 1.22
to 2.54 mmol/L, with a median value of 1.90 (n  8)
(reference range 1.74–2.66 mmol/L) and returned to nor-
mal concentrations afterward. The maximum phosphate
reabsorption rate was decreased, possibly due to the
heterozygous deletion of solute carrier family 34 (type II
sodium/phosphate contransporter), member 1 gene
(SLC34A1) also lost with the deletion (Figure 1A) (16).
During the first 4 days, the child received iv nutrition and
was then switched to breast-feeding. At 4 years of age, he
was more extensively investigated, and it was demon-
strated that serum calcium and PTH levels were normal,
whereas 1,25-dihydroxycholecalciferol (ie, active vitamin
D) was slightly elevated (86 ng/L, normal range 20–80
ng/L). Nephrocalcinosis was absent on ultrasound scan-
ning. We hypothesized that the heterozygous deletion in
FGFR4might be the possible explanation for the observed
transient elevated calcium levels.
Expression profile of FGFRs during fetal renal
development
To elucidate the impact of the observed FGFR4 dele-
tion as well as the transient infantile hypercalcemia, we
studied the renal ontogenesis of FGFRs involved in cal-
cium homeostasis. Figure 2A demonstrates that the gene
expression levels of both FGFR3 and FGFR4 in kidney
samples significantly and positively correlate with gesta-
tional age (GA) with a calculated Pearson r of 0.63 (P 
.0054) and 0.72 (P .0008), respectively. Moreover, the
expression level of both receptors steadily increases during
renal development from 14 to 40 gestational weeks; yet
there is a strikingly greater increase in FGFR4 gene ex-
pressionas comparedwithFGFR3 (slope0.047vs0.0075,
P  .0018). An analogous immunochemical pattern was
observed with light microscopy, revealing a similar
amount of positively stained tubules at 21 weeks of ges-
tation,whereas at aGAof40weeks, FGFR4protein seems
to be more abundantly present as compared with FGFR3
(Figure 2B). Furthermore, in the fetal kidney, FGFR3 pro-
tein expression appears to be limited to the distal tubules,
with some stainings in the glomeruli aswell as themedulla
(Figure 2B). In contrast, FGFR4 was detected in both the
proximal and distal tubules (especially at 40 gestational
wk; Figure 2B) aswell as themedulla (Figure 2B), whereas
the receptor was absent in the glomeruli.
Correlation between FGFR and Klotho expression
It has been previously reported that Klotho is an essen-
tial cofactor for FGF23 signaling (10, 17). As shown in
Figure 3, A and B, Klotho mRNA and protein expression
increases throughout renal development,with lowmRNA
Figure 1. New Sotos syndrome case with infantile hypercalcemia. A,
Extent of 5q35 microdeletion including both NSD1 and FGFR4. B, Dots
represent the calcium level per day during the first weeks of life. Gray
area depicts the normal range of total serum calcium in healthy
neonates, adapted from Roberton’s Textbook of Neonatology (4th ed,
2005, Elsevier Churchill Livingstone).
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levels in the fetal kidneys, consistent with the lack of de-
tectable Klotho protein in fetal and neonatal kidney sam-
ples, at variance with the adult kidneys, in which Klotho
protein is readily detected in renal distal tubules. A sig-
nificant positive correlationwasobservedbetweenKlotho
mRNA andGA (calculated Pearson r 0.80, P .0001).
Moreover, the expression profile ofKlothomRNA signif-
icantly correlates with both FGFR3 (r  0.6, P  .008,
Figure 3C) and FGFR4 (r 0.77, P .0002, Figure 3D)
asdemonstratedwithSpearmancorrelationanalyses, con-
sistent with the key role of Klotho acting as a renal core-
ceptor for FGF23.
Switch in FGFR expression profile during postnatal
development
Next, we compared the FGFR expression profile in fe-
tal, neonatal, and adult kidney samples. As illustrated in
Figure 4A, renal FGFR3 gene ex-
pression was extremely low in both
the early and late stages of gestation,
with a significant 67-fold and 23-
fold lower expression of the receptor
as comparedwith the adult level (P
.0001). In contrast, renal FGFR4
mRNA levels were only 5 times
lower during early gestation as com-
pared with the adult situation (P 
.004), whereas there was no signifi-
cant difference in renal FGFR4 ex-
pression in the late stage of develop-
ment as compared with adult tissue.
Interestingly, during late gestation,
relative FGFR4 expression is 7-fold
higher than that of FGFR3 (P 
.0035, Figure 4B), whereas in adults,
renal FGFR3 expression level was
significantly higher than that of
FGFR4 (P  .0029, Figure 4B).
At the protein level, immunohisto-
chemical studies revealed a similar
trend with more tubules positively
stained for FGFR4 than for FGFR3
at 2 and 9 months of age. Moreover,
FGFR3 and FGFR4 protein localiza-
tion was similar in the neonatal kid-
ney as compared with the fetal kid-
ney. Conversely, FGFR3 protein
expression was markedly increased
in the adult kidney (60yold) andwas
detected in proximal and distal tu-
bules as well as glomeruli, whereas
there was a strong decline in the
number of FGFR4-positive tubules
(Figure 4C). These findings indicate a major molecular
switch in the respective contribution of both FGFRs in
FGF23 signaling during human renal development.
Discussion
Sotos syndrome is a rare genetic disorder characterized by
overgrowth, distinct facial features, and learning disabil-
ities. The clinical features of Sotos syndrome vary between
cases and seem to be independent of genotype (3). In ad-
dition, all features observed in microdeletion cases have
also been reported in individuals with intragenic muta-
tions (3). Still, the individuals with 5q35 microdeletions
are generally more likely to present with severe learning
disabilities and less pronounced overgrowth as compared
Figure 2. Expression of FGFRs in the human fetal kidney. A, FGFR gene expression was studied
using RT-qPCR. Relative expression was calculated as (2-CT)100. Pearson correlation analysis
revealed a significant association between GA and FGFR3 (E; r  0.63, P  .0054) and FGFR4
(f; r  0.72, P  .0008) gene expression. B, Immunostaining of FGFRs in the developing kidney.
C, Secondary antibody control for FGFR staining. Magnification, 20. Arrows indicate a typical
example of a glomerulus (gl), proximal tubule (pt), and distal tubule (dt).
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with patients with intragenic mutations (18). Further-
more, there is a nascent amount of evidence that the phe-
notypic spectrum also encompasses impaired calcium ho-
meostasis during infancy.
Here we report a new Sotos syndrome case, due to a
5q35 microdeletion, with evanescent hypercalcemia. Be-
cause the deletion area included FGFR4, we hypothesized
that dysfunction of this FGF23 receptormight account for
the altered calcium levels. Endocrine calcium homeostasis
is an intricate system involving several regulators and feed-
back loops.Duringhypocalcemia,PTHis stimulatedcaus-
ing active vitamin D levels to rise, which in turn augments
intestinal calcium absorption as well as renal calcium re-
tention (10). In response to elevated serum calcium, os-
teocyte-produced FGF23 is released. Binding of FGF23 to
the FGFR-Klotho complex, including either FGFR3 or
FGFR4, inhibits the synthesis of active 1,25 dihydroxyvi-
tamin D3, both directly by reducing
1-hydroxylase (CYP27B1) expres-
sion and increasing expression of the
vitaminD degrading enzyme, 24–25
hydroxylase (CYP24) but also indi-
rectly by decreasing PTH levels, re-
sulting in a negative calcium balance
(10, 17). Thus, changes in FGF23
signaling will directly impact cal-
cium homeostasis. At present, both
FGF23pathwaydeficiency and renal
FGFR ontogenesis have solely been
studied in animal models, and hu-
man data are lacking. Therefore, we
studied the FGFR3 and FGFR4 ex-
pressionprofile in thedevelopinghu-
man kidney.
Our results revealed a molecular
switch in the FGFR expression pro-
file during human renal develop-
ment. These findings provide com-
pelling evidence that heterozygous
FGFR4 inactivation in humans, as
observed in a 5q35 microdeletion
Sotos syndrome case, might account
for an impaired FGF23 signaling
pathway during early life, causing
transient infantile hypercalcemia.
This notion is corroborated by pre-
vious animal studies. For instance,
Shimada et al (19) reported that cal-
cium levels were elevated in
Fgf23/ mice, which is in accor-
dance with the study by Yuan et al
(20), and an analogous discovery
was made in Klotho-deficient mice
(21). Hypercalcemia was also observed in Ffg23 and
Klotho double-knockout mice (22). Moreover, Haenzi et
al (23) described that the loss of Memo, a recently iden-
tified FGFR regulator, was associated with increased se-
rum calcium. Of interest, the only phenotypic feature that
has been reported in Sotos syndrome cases with microde-
letions is nephrocalcinosis (18). Consistent with the tran-
sient hypercalcemia observed in the described case, aswell
as those previously reported (7, 18), it is likely that alter-
ations of calcium homeostasis might be a distinctive fea-
ture in Sotos syndrome associated with microdeletions.
Moreover, Tatton-Brown et al (5) performed a microsat-
ellite analysis in 33 microdeletion cases and detected a
deletion of FGFR4 in 32 individuals, strengthening the
hypothesis that a mutation in FGFR4, and subsequent
impaired FGF23 signaling, is the culprit in infantile cal-
cium imbalance.
Figure 3. Klotho expression in the developing kidney. Klotho and FGFR gene expressions were
studied using RT-qPCR. A, Relative Klotho expression was calculated as (2-CT)100. Pearson
correlation analysis revealed a significant association between GA and Klotho (r  0.80, P 
.0001). B, Immunostaining of Klotho in fetal (GA of 40 wk) and adult kidney tissue (60 y of age).
Magnification, 20. Arrows indicate a typical example of a glomerulus (gl), proximal tubule (pt),
and distal tubule (dt). C, Positive correlation between Klotho and FGFR3 (Spearman r  0.6, P 
.008). D, Positive correlation between Klotho and FGFR4 (Spearman  0.77, P  .0002).
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Our study is one of the first to provide a detailed descrip-
tionofhumanrenalFGFRontogeny.Cancilla et al (24)dem-
onstrated thatFGFR3 andFGFR4 gene expression could be
detected in the developing rat kidney and increased during
development. Furthermore, at embryonic day 20, FGFR3
protein expressionwas present in the distal tubules,whereas
immunostainingwas absent in the proximal tubules. In con-
trast, FGFR4 immunoreactivity was
present inbothdistal andproximal tu-
bules (24). This expression pattern is
similar to our observations. In addi-
tion, other studies have also demon-
strated the expression of FGFR4 dur-
ing renal development in rat andmice
(25, 26), and recently it was reported
in a zebrafish study that fgf23 and
klotho were continuously expressed
in the developing kidney (27). Several
decades ago, Partanen et al (28) re-
ported the expression of both FGFR3
and FGFR4 in the human fetal kidney
(GA 17–18 wk), and they described
that organ-specificFGFR4 expression
highly differs from other FGFRs. In a
follow-up study, they investigated the
expression of FGFR4 in the develop-
ing mouse, and, similar to our find-
ings, they demonstrated that theFgfr4
gene expression in themurine embryo
steadily increasedduringdevelopment
andwas hardly detectable in newborn
and2-day-oldmice (29).Clearly, tem-
poral FGFR expression is conserved
among species and is subjected to
change during both early renal devel-
opment and aging.
The present study has some draw-
backs. First of all, calcium homeosta-
sis is a complex system involving a
myriadofnegative feedback loopsand
multiple hormones (10), but unfortu-
nately, during the early clinical inves-
tigations, serum levels of FGF23, sol-
uble Klotho, and active vitamin D
have not beendetermined. Second,we
could not get access to mRNA from
early postnatal kidneys, limiting the
latter part of our study solely to pro-
tein expression. Still, this study is the
first to concisely describe postnatal se-
rum calcium levels in an individual
with Sotos syndrome, and owing to
the availability of a unique and pre-
cioushumankidneycollection,wehavebeenable topartially
dissect and elucidate the expression profile of FGFRs during
human renal development.
In conclusion, we have demonstrated the presence of
transient infantile hypercalcemia in a 5q35 microdeletion
case of Sotos syndrome, which included a deletion of
FGFR4. Furthermore, we found that FGFR4 is highly ex-
Figure 4. Renal FGFR expression in fetal, neonatal, and adult tissue. FGFR gene expression was
studied using RT-qPCR. A, Expression of FGFRs in fetal (early GA of 14–16 wk; late GA of 38–40 wk)
and adult renal tissues. Relative expression was calculated with the 2-CT method. Data are
expressed as fold change relative to adult values. Statistical analysis was performed via one-way
ANOVA followed by Bonferroni’s multiple comparison test. B, FGFR4 expression in fetal (late, GA of
38–40 wk) and adult tissue as compared with FGFR3. Relative expression was calculated with the
2-CT method. Data are expressed as fold change relative to FGFR3 levels. Statistical analysis was
performed via an unpaired Student’s t test. Results are presented as mean SEM of two
independent determinations performed in duplicate. ***, P .0005; **, P .008; *, P .004. C,
Immunostaining of FGFRs in neonatal and adult kidney tissue (60 y of age). Magnification,20.
Arrows indicate a typical example of a glomerulus (gl), proximal tubule (pt), and distal tubule (dt).
E1366 Mutsaers et al Ontogeny of FGFR3 and -4 in Human Kidney J Clin Endocrinol Metab, July 2014, 99(7):E1361–E1367
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 28 August 2014. at 07:19 For personal use only. No other uses without permission. . All rights reserved.
pressed in fetal and neonatal kidney, whereas FGFR3 ex-
pression is highest in adult tissue. This indicates that there
is a developmental switch in the contribution of both FG-
FRs to FGF23 signaling during aging,which could explain
the fleeting hypercalcemia. These findings provide a novel
and intriguing insight into FGF23-mediated calcium
homeostasis.
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